The White House launched TrumpRx, an online drug‑pricing portal offering discounted cash prices on a selected list of medicines, but early analysis shows limited benefit for many insured patients. Multiple reporting outlets compared the platform’s listed savings to generic retail prices and found several branded drugs were already cheaper in generic form. STAT and other outlets flagged that TrumpRx’s model does not sell drugs directly and that the principal beneficiaries are uninsured, cash‑paying consumers rather than the majority whose costs are mediated by insurance. Federal officials said they aim to expand the program’s roster of manufacturers and deals. The rollout underscores the complexity of U.S. drug pricing and the limited reach of direct‑to‑consumer discount schemes unless tied to broader structural reforms in formularies and insurance coverage.